Evidence map›Paper›PMID 41504239›Full record

ArticleHaematologica2026

Ethnicity affects relapse-free survival in immunemediated thrombotic thrombocytopenic purpura.

Júlia Weisinger, Florian Blanchard, Benoit Suzon, Christophe Deligny, Jehane Fadlallah, François Provôt, Pascale Poullin, Manon Marie, David Ribes, Gabriel Choukroun and 35 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors.

Júlia WeisingerCentre de Référence des Microangiopathies Thrombotiques, Service d'hématologie, Hôpital Saint Antoine, APHP and Sorbonne Université (AP-HP.6), Paris.
Florian BlanchardSorbonne Université, GRC 29, Groupe de Recherche Clinique en Anesthésie Réanimation médecine périopératoire, ARPE, F-75013 Paris, France; Hôpital La Pitié Salpêtrière, APHP DMU DREAM, Department of Anesthesiology and Critical Care, F-75013 Paris.
Benoit SuzonDepartment of Internal Medicine, Martinique University Hospital, Fort-de-France, Martinique.
Christophe DelignyDepartment of Internal Medicine, Martinique University Hospital, Fort-de-France, Martinique.
Jehane FadlallahService d'Immunologie Clinique, Hôpital Saint-Louis, APHP, Paris.
François ProvôtService de Néphrologie, Hôpital Albert Calmette, Lille.
Pascale PoullinService d'Hémaphérèse, Hôpital de La Conception, CHU de Marseille, Marseille.
Manon MarieService de Médecine Interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon.
David RibesDepartment of Nephrology and Organ Transplantation, Referral Centre for Rare Kidney Diseases, University Hospital of Toulouse, INSERM U1297, Toulouse.
Gabriel ChoukrounService de Néphrologie Médecine Interne Dialyse Transplantation, CHU Amiens Picardie et laboratoire MP3CV, UPJV, Amiens.
Yahsou DelmasService de Néphrologie, CHU Bordeaux, Bordeaux.
Elie AzoulayMédecine Intensive Réanimation, Hopital Saint Louis, APHP, Paris.
Ygal BenhamouService de Médecine Interne, CHU Charles Nicolle, Rouen.
Maximilien GrallDepartment of Internal Medicine, CHU Rouen, Rouen.
Jean-Michel HalimiService de Néphrologie-Hypertension, Dialyses, Transplantation Rénale, CHRU Tours, Tours.
Moglie Le QuintrecCentre Hospitalier Universitaire de Lapeyronie, Département de Néphrologie Dialyse et Transplantation Rénale, Montpellier.
Aude ServaisService de Néphrologie et Transplantation, Hopital Necker, APHP, Paris.
Thomas PapoService de Médecine Interne, Hopital Bichat, APHP, Paris.
Camille LepartService de Médecine Interne et Immunologie Clinique, CHU de Rennes, Rennes.
Claire CarteryService de Néphrologie, CH de Valenciennes, Valenciennes.
Valérie ChateletDepartment of Adult Nephrology, CHU de Caen, Caen.
Jean-Francois AugustoService de Néphrologie-Dialyse-Transplantation, CHU d'Angers, Angers.
Simon VilleDepartment of Adult Nephrology and Immunology, CHU de Nantes, Nantes.
Pierre PerezService de Médecine Intensive Réanimation, Hopital Brabois, Nancy.
Loïc LièvreService de Néphrologie, Hopital Maison Blanche, Reims.
Mathieu LegendreService de Néphrologie, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon.
Anne RumplerService d'Hématologie, CHRU de Besancon, Besancon.
Alexandre HertigDepartment of Renal Transplantation, Hopital Pitié-Salpetrière, APHP and Sorbonne University, Paris.
Virginie RieuService de Médecine Interne, CHU de Clermont-Ferrand, Clermont-Ferrand.
Arnaud JaccardService d'Hématologie et de Thérapie Cellulaire, CHU Limoges, Limoges.
Patricia ZunicDepartment of Heamatology, Sud Reunion University Hospital, Saint Pierre, La Réunion.
Laurent GilardinService d'Onco-Hématologie, Hopital Saint-Louis, APHP, Paris.
Nihal MartisService de Médecine Interne et d'Immunologie Clinique, Hopital de Nice, Nice.
Sara Rovira PuigLaboratory for Thrombosis Research, IRF Life Sciences, KU Leuven Campus Kulak Kortrijk, Kortrijk.
Rutuja GupteInstitute of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden.
Maria Del Mar Tolos GarciaLaboratory of Experimental Hematology, University of Antwerp, Antwerp.
Margot DierickxDepartment of Molecular Hematology, Sanquin Research and Landsteiner Laboratory, Amsterdam.
Daniela GrecoAhead Therapeutics SL, Barcelona.
Timon AlbrechtIrish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin.
Andreea-Adela IcleanuDepartment of Internal Medicine and Hematology and Research Group for Immunology and Hematology, Semmelweis University - Eötvös Loránd Research Network (Office for Supported Research Groups), Budapest, Hungary.
Raïda BouzidCentre de Référence des Microangiopathies Thrombotiques, Service d'hématologie, Hôpital Saint Antoine, APHP and Sorbonne Université (AP-HP.6), Paris, France; INSERM Unité Mixte de Recherche (UMRS) 1138, Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Paris.
Bérangère JolyCentre de Référence des Microangiopathies Thrombotiques, Service d'hématologie, Hôpital Saint Antoine, APHP and Sorbonne Université (AP-HP.6), Paris, France; INSERM Unité Mixte de Recherche (UMRS) 1138, Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Paris, France; Service d'Hématologie biologique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris Nord, Université Paris Cité, Paris.
Agnès VeyradierCentre de Référence des Microangiopathies Thrombotiques, Service d'hématologie, Hôpital Saint Antoine, APHP and Sorbonne Université (AP-HP.6), Paris, France; INSERM Unité Mixte de Recherche (UMRS) 1138, Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Paris, France; Service d'Hématologie biologique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris Nord, Université Paris Cité, Paris.
Adrien PicodCentre de Référence des Microangiopathies Thrombotiques, Service d'hématologie, Hôpital Saint Antoine, APHP and Sorbonne Université (AP-HP.6), Paris, France; Medico-surgical ICU, University Hospital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny.
Paul CoppoCentre de Référence des Microangiopathies Thrombotiques, Service d'hématologie, Hôpital Saint Antoine, APHP and Sorbonne Université (AP-HP.6), Paris, France; INSERM Unité Mixte de Recherche (UMRS) 1138, Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Paris. paul.coppo@aphp.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is caused by a severe, antibody-mediated deficiency of ADAMTS13 activity. The B-cell depleting agent rituximab is effective in restoring ADAMTS13 activity and therefore preventing relapses. However, the risk of relapse appears heterogeneous among patients, although the underlying causes are elusive. Preliminary reports suggested that African ancestry could be associated with decreased relapse-free survival (RFS). Data from the registry of the French National Thrombotic Microangiopathy Reference Center were used to further address the role of ethnicity on response and RFS after rituximab administration in the acute as well as in the preemptive setting. A total of 790 patients (134 patients of African ancestry and 656 patients of European ancestry) were included in the study. Time from rituximab administration to ADAMTS13 recovery was comparable between the two cohorts. Patients of African ancestry had inferior 3-year RFS after the first rituximab-treated episode compared to patients of European ancestry (P<0.05). In multivariate analyses, African ancestry was identified as an independent risk factor for relapse (hazard ratio [HR]=1.36; P<0.05), as well as male sex (HR=1.21; P<0.05) and type of index episode treated by rituximab (relapsed disease vs. initial episode, HR=1.62; P<0.05). Moreover, time to relapse shortened progressively after consecutive courses of rituximab, regardless of ethnicity (P<0.05). These results indicate that ethnicity affects RFS with patients of African ancestry relapsing earlier, suggesting that a closer ADAMTS13 monitoring might be necessary in high-risk patients.

Indexed as

Purpura, Thrombotic ThrombocytopenicADAMTS13 ProteinAdultAgedBlack PeopleDisease-Free SurvivalFemaleFranceHumansMaleMiddle AgedRecurrenceRegistriesRituximabWhite PeopleADAMTS13 ProteinADAMTS13 protein, humanRituximab

Identifiers

PMID41504239
PMCPMC13136792

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.